At PureTech, we are creating new categories of therapeutics derived from our deep understanding of the Brain-Immune-Gut (BIG) axis

Our Publications


PureTech's Components of Value

 

Learn more about our unique discovery process

Wholly Owned Pipeline

Our programs
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
LYT-100
Deupirfenidone
Lymphatic flow disorders, incl. lymphedema
Initiation of Phase 2a POC study in H2 2020
LYT-100
Deupirfenidone
Long COVID1 respiratory complications & related sequelae
Initiation of Phase 2 study in H2 2020
LYT-100
Deupirfenidone
Other fibrotic & inflammatory disorders, such as IPF
LYT-200
Anti-Galectin-9 MAb
Solid tumors
IND & initiation of Phase 1 study in 2020
LYT-210
Anti-Delta-1 MAb
Solid tumors
LYT-300
Oral Allopregnanolone
Neurological indications

Cash at Puretech Parent Level

Founded Entities

1. Funding figure includes private equity financings, public offerings or grant awards. Funding figure excludes upfront payments and future milestone considerations received in conjunction with partnerships and collaborations such as those with Roche, Boehringer Ingelheim, Imbrium Therapeutics L.P., Shionogi & Co., Ltd. or Eli Lilly. Funding figure assumes all future tranches are funded in the Vor Series B financing round. Calculated as of January 1, 2017 to June 30, 2020.

2. PureTech Level Cash Reserves at September 30, 2020 represent cash balances and short-term investments held at PureTech Health LLC, PureTech Management, Inc., PureTech Health PLC, PureTech Securities Corporation of $372.0 million and held at PureTech LYT Inc., our internal pipeline, of $15.2 million, all of which are wholly owned entities of PureTech, excluding cash balances and short-term investments of $38.3 million held at Controlled Founded Entities which are not wholly owned.

CASE STUDIES

DISCOVERY REINVENTED

New mechanism for treating psychosis and cognitive impairments (KarXT)

Open Case Study

The Challenge

Psychosis, negative symptoms, and cognitive impairments in schizophrenia, Alzheimer’s disease and other mental illnesses remain poorly treated

There are approximately 2.7M living with schizophrenia and 5.7M living with Alzheimer's in the US

Existing Approaches

Antipsychotics are the mainstay therapy targeting dopamine pathways, however with no new treatment mechanism in 60 years, the prognosis for patients remain poor

Cuurent antipsychotics only address psychosis (positive symptoms) and are associated with serious side effects such as sedation, extrapyramidal side effects such as motor rigidity, tremors and slurred speech, and weight gain 

The Big Idea

A class of medicines (M1/M4 agonists) that showed enormous potential in clinical studies was never developed due to tolerability issues.

We asked “What if you you could selectively target M1/M4 receptors in the central nervous system without affecting the peripheral tissues where most side effects occur?”

The Result

Karuna is developing a potentially first-in-class oral modulator of muscarinic receptors

KarXT combines xanomeline, a novel muscarinic receptor agonist, with trospium chloride, a muscarinic receptor antagonist that acts peripherally and does not measurably cross the blood-brain barrier

Selective mTORC1 Inhibitors (resTORbio)

Open Case Study

The Challenge

Many of the afflictions of a rapidly aging population – from declines in cognition, to immunosenescence and cancer – remain poorly addressed. One such indication is respiratory tract infection, or RTI, a leading cause of mortality in elderly people

Existing Approaches

Limited therapeutic options exist today to prevent and treat viral respiratory tract infections.

Some vaccines protect against specific viruses; however there is no available treatment for most RTIs, a leading cause of mortality in high risk, elderly populations.

The Big Idea

Can we develop an anti-viral that works by boosting the immune system?

The Result

A new approach in targeting the mTOR pathway by selectively targeting TORC1, linked to increased lifespan and other beneficial effects. We are focusing initially on the reduction of RTIs in elderly individuals at increased risk of RTI related morbidity and mortality. Our selective mTORC1 inhibition program has potential in other aging related indications including cognition, cardiovascular and cancer.

Rationally defined, immune modulating non-pathogenic human microbes (VE202)

Open Case Study

The Challenge

The human microbiome is increasingly implicated in various immune-mediated disease states

Vedanta has discovered specific bacteria that induce T regs (which form the basis for Vedanta's IBD and food allergy candidates) and CD8+ cells (which form the basis for Vedanta's IO candidate)

Existing Approaches

Many existing IBD interventions are limited by toxicities and systemic immune suppression

Food Allergy treatment today primarily centers around allergen avoidance, and new immunotherapies focused on desensitization may note prove cost-effective relative to this approach

Checkpoint Inhibitors are only effective in 20-30% of patients

C. difficile is typically treated using antibiotics (damage the microbiome and leave patients vulnerable to re-infection) or FMT (uncharacterized safety issues)

The Big Idea

What if we could treat immune and infectious disease by mimicking the ways in which the gut microbiota maintains a healthy immune system in humans?

The Result

Vedanta is developing a potentially new category of therapies based on a rationally-defined consortia of human microbiome-derived bacteria

Defined consortia have potential to shift microbiota, stimulate immune responses, and provide colonization resistance against infectious pathogens

Clinical results for VE303, VE800, and VE416 are anticipated in 2020

Foundational patents issued in key territories 

Targeting immunologically silent tumors with first-in-class mAbs (LYT-200)

Open Case Study

The Challenge

Low five year survival rate for many aggressive solid tumors, including metastatic pancreatic and colorectal cancer, and metastatic cholangiocarcinoma

Many aggressive solid tumors do not benefit from approved immuno-oncology agents

Low response rate to immunotherapy

Existing Approaches

"Cold" tumors lack cancer-killing immune cells

Finding targets that suppress multiple immunosuppressive pathways simultaneously has proven challenging, and combination therapies are limited by toxicity

The Big Idea

Can we target the immunosuppressive cells that solid, malignant tumors establish to ward off the body’s natural defenses?

The Result

Developing first-in-class fully human mAbs targeting immunologically silent tumors with galectin-9 and immunosuppressive γδ T cells that mediate immunosuppression through multiple mechanisms and has the potential for single efficacy as well as combinations.

 

Relationships with several pharma companies or their investment arms